BioCryst to Present at the BioCentury NewsMakers in the Biotech Industry Conference
BioCryst Pharmaceuticals, Inc. is a leader in the use of crystallographyand structure-based drug design for the development of novel therapeutics totreat cancer, cardiovascular diseases, autoimmune diseases, and viralinfections. The company is advancing multiple internal programs towardpotential commercialization including Fodosine(TM) in oncology, BCX-4208 intransplantation and autoimmune diseases and peramivir in seasonal and life-threatening influenza. BioCryst has a worldwide partnership with Roche for thedevelopment and commercialization of BCX-4208, and is collaborating withMundipharma for the development and commercialization of Fodosine(TM) inmarkets across Europe, Asia, Australia and certain neighboring countries. InJanuary, 2007 the U.S. Department of Health and Human Services (DHHS) awardeda $102.6 million, four-year contract to BioCryst for advanced development ofperamivir to treat seasonal and life-threatening influenza. In February 2007BioCryst established a partnership with Shionogi & Co., to develop andcommercialize peramivir in Japan. For more information about BioCryst, pleasevisit the company's web site at http://www.biocryst.com.
This press release contains forward-looking statements, includingstatements regarding future results, performance or achievements. Thesestatements involve known and unknown risks, uncertainties and other factorswhich may cause our actual results, performance or achievements to bematerially different from any future results, performances or achievementsexpressed or implied by the forward-looking statements. These statementsreflect our current views with respect to future events and are based onassumptions and subject to risks and uncertainties. Given these uncertainties,you should not place undue reliance on these forward-looking statements. Someof the factors that could affect the forward-looking statements containedherein include that the Phase II clinical trials of peramivir may not besuccessful, that the Phase II trial of BCX-4208 for psoriasis may not besuccessfully completed, that development and commercialization of Fodosine(TM)in both T-ALL and CTCL may not be successful, that we may not resolvesatisfactorily the particulate matter issue with the intravenous formulationof Fodosine(TM), that DHHS could reduce or eliminate funding for peramivir,that we or our licensees may not be able to enroll the required number ofsubjects in planned clinical trials of our product candidates and that suchclinical trials may not be successfully completed, that BioCryst or itslicensees may not commence as expected additional human clinical trials withour product candidates, that our product candidates may not receive requiredregulatory clearances from the FDA, that ongoing and future clinical trialsmay not have positive results, that we may not be able to completesuccessfully the Phase IIb trials for Fodosine(TM) that are currently plannedto be pivotal, that we may not be able to commence the proposed Phase IIItrial for peramivir within the time frame we currently expect or at all, thatwe may not be able to announce preclinical developments for additionalcompounds by year-end 2007 as currently proposed, that we or our licensees maynot be able to continue future development of our current and futuredevelopment programs, that our development programs may never result in futureproduct, license or royalty payments being received by BioCryst, that BioCrystmay not reach f
You May Also Like